Development and characterization of polyclonal antibody against human kappa light chain in rabbit

Document Type : Original Article

Authors

1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

3 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

4 Immunology Laboratory, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

5 Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Polyclonal antibodies against kappa light chain are used to diagnose diseases producing free light chain. The kappa and lambda light chains are products of immunoglobulin synthesis and released into the circulation in minor amounts such as serum, cerebrospinal fluid, urine and synovial fluid in normal condition. The purpose of this study was the production and purification of polyclonal immunoglobulin G (IgG) against human kappa light chains. In this study, early human IgG was purified by ion-exchange chromatography, reduced with Dithiothreitol and heavy and light chains were separated with size-exclusion chromatography. Afterward, affinity chromatography with protein L Sepharose at pH 2.00 was displayed to be a dominant condition for the separation and purification of the kappa light chain of immunoglobulins from human serum. Eventually, the rabbit was immunized by human kappa light chains. The rabbit IgG was purified and labeled with horseradish peroxidase (HRP). Direct enzyme-linked immunosorbent assay was planned to determine the titer of HRP conjugated rabbit IgG against the human kappa light chain. The optimum titer of anti-kappa IgG was 1:16000. At the result, purified polyclonal anti-kappa is useful tool in biomedical and biochemical researches and diagnostic kits.

Keywords

Main Subjects

References

  1.  

    1. Esparvarinha M, Nickho H, Mohammadi H, et al. The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomed Pharmacother 2017; 91: 632-644.
    2. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006; 533(1-3): 319-326.
    3. Nasiri H, Valedkarimi Z, Aghebati-Maleki L, et al. Production and purification of polyclonal antibody against F (ab') 2 fragment of human immunoglobulin G. Vet Res Forum 2017; 8 (4) 307-312.
    4. Abe M, Goto T, Kosaka M, et al. Differences in kappa to lambda (kappa: lambda) ratios of serum and urinary free light chains. Clin Exp Immunol 1998; 111(2): 457-462.
    5. Valedkarimi Z, Nasiri H, Aghebati-Maleki L, et al. Production and characterization of anti-human IgG F (ab’) 2 antibody fragment. Hum antibodies 2018; 26(4): 171-176.
    6. Sinclair D, Dagg J, Smith J, et al. The incidence and possible relevance of Bence-Jones protein in the sera of patients with multiple myeloma. Br J Haematol 1986; 62(4): 689-694.
    7. Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010; 85(10): 787-790.
    8. Goffette S, Schluep M, Henry H, et al. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75(2): 308-310.
    9. Hopper JE, Sequeira W, Martellotto J, et al. Clinical relapse in systemic lupus erythematosus: Correlation with antecedent elevation of urinary free light-chain immunoglobulin. J Allergy Clin Immunol 1989; 9(4): 338-350.
    10. Campbell JP, Cobbold M, Wang Y, et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013; 391(1-2): 1-13.
    11. Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23(2): 215-224.
    12. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3(6): 1684-1690.
    13. Sadeghi S, Aghebati-Maleki L, Nozari S, et al. A methodological approach for production and purification of polyclonal antibody against dog IgG. Vet Res Forum 2018; 9 (1) 13-18
    14. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97(9): 2900-2902.
    15. Maleki LA, Majidi J, Baradaran B, et al. Production an characterization of murine monoclonal antibody against synthetic peptide of CD34. Hum Antibodies 2013; 22(1-2): 1-8.
    16. Zemlin AE, Ipp H, Rensburg MA, et al. Serum free light chains in patients with HIV infection: Their association with markers of disease severity and antiretroviral use. J Clin Pathol 2015; 68(2):148-153.
    17. Bibas M, Trotta MP, Cozzi-Lepri A, et al. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 2012; 87(8): 749-753.
    18. Nilson B, Solomon A, Bjorck L, et al. Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J Biol Chem 1992; 267(4): 2234-2239.
    19. Liu H, Gaza-Bulseco G, Chumsae C. Analysis of reduced monoclonal antibodies using size exclusion chromato-graphy coupled with mass spectrometry. Am Soc Mass Spectrom 2009; 20(12): 2258-2264.
Veterinary Research Forum
Volume 10, Issue 3
September 2019
Pages 207-211

Files

History

  • Receive Date: 26 February 2018
  • Revise Date: 24 November 2018
  • Accept Date: 04 December 2018
  • First Publish Date: 01 September 2019

Share

How to cite

Statistics